In April, The Michael J. Fox Foundation (MJFF) announced a major biomarker breakthrough, opening a new chapter for Parkinson’s research — with the promise of better drug development and care for all people and families living with the disease.
With the new test to detect abnormal alpha-synuclein in spinal fluid, validated by MJFF’s Parkinson’s Progression Markers Initiative (PPMI), researchers can objectively define and monitor this pathology for the first time in the living body. The discovery ushers in research on a new generation of treatments that can be tailored to disease subtypes and even unlock the potential to prevent Parkinson’s altogether.
In audio from this special edition webinar of our Third Thursdays Webinars series, listen as MJFF and PPMI experts discuss this groundbreaking discovery, answer your questions and explain the promise this research holds for all people living with Parkinson’s — at every stage of their journey.
If you’d rather listen on the go, subscribe to our Michael J. Fox Foundation Parkinson's Podcast on iTunes or through any podcast app on your smartphone or tablet. And if you enjoyed what you heard, share it with a friend or leave a review on iTunes. It helps listeners like you find and support our mission.
Expert Panelists:
The Michael J. Fox Foundation’s vice president of research communications, Maggie McGuire Kuhl, leads the discussion with:
-
Sohini Chowdhury; chief program officer, MJFF
-
Rachel Dolhun, MD, DipABLM; senior vice president of medical communications, MJFF
-
Ken Marek, MD; principal investigator, Parkinson’s Progression Markers Initiative; president and co-founder, Institute for Neurodegenerative Disorders
View a transcript of this podcast.
PPMI is enrolling people with and without Parkinson's disease. Join the study that's changing everything. michaeljfox.org/podcast-ppmi